[1] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China.2015[J].Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[2] Chang SS,Bochner BH,Chou R,et al. Treatment of non-metastatic muscle-invasive bladder cancer:AUA/ASCO/ASTRO/SUO Gui-deline[J].J Urology,2017,198(3):552-559.DOI:10.1016/j.juro.2017.04.086.
[3] Flaig TW,Spiess PE,Agarwal N,et al. National comprehensive cancer network.bladder cancer (version 3.2018)[M/OL][2018-06-18].http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.2018,V3.
[4] Ploussard G,Daneshmand S,Efstathiou JA,et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer:a systematic review[J].Eur Urol,2014,66(1):120-137.DOI:10.1016/j.eururo.2014.02.038.
[5] Clark PE,Spiess PE,Agarwal N,et al. National Comprehensive Cancer Network. Bladder Cancer (Version 2.2016) M/OL][2018-06-18].http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf,2016,V2.
[6] Mak RH,Zietman AL,Heney NM,et al. Bladder preservation:optimizing radiotherapy and integrated treatment strategies[J].BJU international,2008,102(9 pt B):1345-1353.DOI:10.1111/j.1464-410x.2008.07981.x.
[7] Arcangeli G,Arcangeli S,Strigari L.A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)[J].Crit Rev Oncol Hematol,2015,94(1):105-115.DOI:10.1016/j.critrevonc.2014.11.007.
[8] Hafeez S,Horwich A,Omar O,et al. Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder[J].Br J Cancer,2016,114(12):e24.DOI:10.1038/bjc.2016.132.
[9] Alfred Witjes J,Lebret T,Comperat EM,et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J].Eur Urol,2017,71(3):462-475.DOI:10.1016/j.eururo.2016.06.020.
[10] Malmstr m PU.Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis[J].Scand J Urol Nephrol Suppl,1988,112:1-55.
[11] Mak RH,Hunt D,Shipley WU,et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy:a pooled analysis of Radiation Therapy Oncology Group protocols 8802,8903,9506,9706,9906,and 0233[J].J Clin Oncol,2014,32(34):3801-3809.DOI:10.1200/JCO.2014.57.5548.
[12] James ND,Hussain SA,Hall E,et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer[J].N Engl J Med,2012,366(4):1477-1488.DOI:10.1056/NEJMc 1206002.
[13] Coppin CM,Gospodarowicz MK,James K,et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group[J].J Clin Oncol,1996,14(11):2901-2907.DOI:10.1200/JCO.1996.14.11.2901.
[14] Shipley WU,Prout GR,Einstein AB Jr., et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery[J].JAMA,1987,258(7):931-935.
[15] Pisters LL,Westney L.The management of locally recurrent invasive bladder cancer following radical cystectomy[J].Semin Urol Oncol,1996,14(2):112-119.
[16] Griffiths G,Hall R,Sylvester R,et al. International phase Ⅲ trial assessing neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer:long-term results of the BA06 30894 trial[J].J Clin Oncol,2011,29(16):2171-2177.DOI:10.1200/JCO.2010.32.3139.
[17] Neoadjuvant chemotherapy in invasive bladder cancer:update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration[J].Eur Urol,2005,48(2):202-205,205-206.
[18] Giacalone NJ,Shipley WU,Clayman RH,et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer:an updated analysis of the massachusetts general hospital experience[J].Eur Urol,2017,72(3):e64-e65.DOI:10.1016/j.eururo.2017.06.007.
[19] Efstathiou JA,Spiegel DY,Shipley WU,et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer:the MGH experience[J].Eur Urol,2012,62(2):705-711.DOI:10.1016/j.eururo.2012.04.054. |